InvestorsHub Logo
Followers 89
Posts 17436
Boards Moderated 0
Alias Born 09/06/2006

Re: sentiment_stocks post# 183731

Monday, 07/23/2018 4:19:23 PM

Monday, July 23, 2018 4:19:23 PM

Post# of 702473
If you want to keep bringing this up, then...

So to getting down to it… they were granted an authorization for use. There were criteria that had to be fulfilled to have the marketing authorization granted. It seems the company thought that criteria would be very easily fulfilled.


They later admitted they were granted an import/export license subject to some conditions on clean room validation.

. NWBT has received such "Autorisation from the BAG as an import/export authorization ("Autorisation pour activit transfrontali res avec des transplants ). This authorization is conditional upon certain implementation commitments that NWBT will have to fulfill before the import/export activity can proceed (e.g., finalizing its pending arrangements for a clean-room suite for processing of patients' immune cells.) The process of this fulfillment is under way.

The Authorization will allow the Company to export patients' immune cells and tumor tissue for vaccine manufacturing in the USA, and import the patients ' DCVax®Brain finished vaccine into Switzerland. The safety and efficiy had not yet been evaluated, as that is not needed for an import/export license.



The safety and efficacy had not been evaluated and NWBO knew it:

In the BAG's processing and decision on the Company's "Autorisation application and data, Swissmedic ("Institut Suisse des Agents Therapeutiques ) only conducted the inspection and did not conduct any evaluation ofthe safety or efficacy of
DCVax®-Brain.



Then you want to say they expected safety and efficacy to be easy to prove? Are you kidding me? Safety and efficacy is what these trials are all about. That would be as absurd as thinking that because the FDA allows a trial to run that getting the approval should be an easy matter.

As far as the BS about the media being mistaken, here is the top of the NWBO PR:

Media Contact: Linda Powers 240-441-6047 240-497-4060

World's First Therapeutic Vaccine for Brain Cancer Commercially Available to Patients in Switzerland

Swiss "Authorization for Use" Approved for DCVax®-Brain



LP has her name at the very top, she was the frigen owner, and the PR was pure scam.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News